Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz

Building in oncology, Jazz obtains targeted glioma therapy under FDA review

March 5, 2025 9:02 PM UTC

Three months after Chimerix revealed that its discussions with FDA outlined an unexpected path to accelerated approval of its brain cancer therapy, Jazz is buying the company for about $935 million.

The deal values Chimerix Inc. (NASDAQ:CMRX) at $8.55 per share, a premium of 72% over Tuesday’s close and roughly 10 times its value in early December. That was before the biotech announced that it intended to submit selective DRD2 antagonist dordaviprone (ONC201) for FDA approval to treat H3 K27M-mutant diffuse glioma, a hard-to-treat cancer that most often appears in pediatric patients and young adults...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article